GLP-1 injections recalled nationwide. See affected products
19 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
12 trends tracked about this subject — the full history, oldest to newest below.
19 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Federal regulators face mounting scrutiny as unapproved weight-loss drugs and new safety warnings enter public focus.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly reports that its new combination obesity regimen, EloraTZP, outperformed tirzepatide in a mid-stage clinical trial.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent coverage examines rapid weight regain after discontinuing GLP-1 medications like Ozempic, semaglutide, and tirzepatide.
Growing concerns emerge over the 'Ozempidemic' as users report intense cravings and safety risks associated with GLP-1 weight-loss medications.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Researchers screening 6,000 existing medications have identified potential anti-aging properties in common drugs, including GLP-1 weight loss treatments.